Di Chen
State Key Laboratory Of Bioactive Substances And Functions Of Natural Medicines, Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, 100050, China
Beijing, 100050, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Puerarin Inhibits NLRP3-Caspase-1-GSDMD-Mediated Pyroptosis via P2X7 Receptor in Cardiomyocytes and Macrophages.
Journal: International journal of molecular sciences
Published: June 20, 2023
Dan-Shen-Yin Granules Prevent Hypoxia-Induced Pulmonary Hypertension via STAT3/HIF-1α/VEGF and FAK/AKT Signaling Pathways.
Journal: Frontiers in pharmacology
Published: January 27, 2022
Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.
Journal: Acta pharmacologica Sinica
Published: September 06, 2021
DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Journal: European journal of pharmacology
Published: September 02, 2021
Systematic analysis of molecular mechanism of resveratrol for treating pulmonary hypertension based on network pharmacology technology.
Journal: European journal of pharmacology
Published: April 10, 2020
Systematic Elucidation of the Mechanism of Genistein against Pulmonary Hypertension via Network Pharmacology Approach.
Journal: International journal of molecular sciences
Published: September 09, 2019
Puerarin protects pulmonary arteries from hypoxic injury through the BMPRII and PPARγ signaling pathways in endothelial cells.
Journal: Pharmacological reports : PR
Published: October 09, 2018
A novel hypertensive crisis rat model established by excessive norepinephrine infusion and the potential therapeutic effects of Rho-kinase inhibitors on it.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: September 14, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026